Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : T/FIF, a New Plateau -- Ignore unavailable to you. Want to Upgrade?

To: tom pope who wrote (2122)	6/13/2003 11:56:53 AM
From: scaram(o)uche	Read Replies (1) \| Respond to of 2243

that's the entire point........... I don't know. I'm just searching for ANY explanation for how the stock could have been held at this artificial capitalization. The shorts claim that there was data in hand re. drug interactions BEFORE a "subsequent 6-week prophylaxis study found that pleconaril induces cytochrome P-450 3A enzymes". Message 19029482 edit: If you read the minutes from the Advisory Committee, a FDA rep. tells the story just like Hayden. And the company says that the accusation is not founded and that they will defend aggressively.